Download PDF
Horm Metab Res 2017; 49(03): 208-213
DOI: 10.1055/s-0042-124189
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Changes in Body Mass Index in Pheochromocytoma Patients Following Adrenalectomy

Ariadni Spyroglou
1   Medizinische Klinik und Poliklinik IV, Endocrine Research Unit, Klinikum der Universität München, LMU, Munich, Germany
,
Christian Adolf
2   Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Würzburg, Germany
,
Stefanie Hahner
2   Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Würzburg, Germany
,
Marcus Quinkler
3   Endocrinology in Charlottenburg, Berlin, Germany
,
Roland Ladurner
4   Klinik für Allgemeine, Unfall- und Wiederherstellungschirurgie, Klinikum der Universität München, LMU, Munich, Germany
,
Martin Reincke
1   Medizinische Klinik und Poliklinik IV, Endocrine Research Unit, Klinikum der Universität München, LMU, Munich, Germany
,
Felix Beuschlein
1   Medizinische Klinik und Poliklinik IV, Endocrine Research Unit, Klinikum der Universität München, LMU, Munich, Germany
› Author Affiliations
Further Information

Publication History

received 19 September 2016

accepted 13 December 2016

Publication Date:
21 February 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Catecholamine excess from pheochromocytoma results in cardiovascular symptoms such as arterial hypertension and tachycardia and induces metabolic alterations including glucose intolerance and increase in resting metabolic rate. The objective of our study was to investigate the effect of surgical cure of pheochromocytoma on body-mass-index and the correlation of body-mass-index changes to preoperative endocrine parameters. Pheochromocytoma patients from the Munich ENSAT Registry were matched (1:2) for age and gender to patients from the German Conn’s Registry, who had undergone surgery for aldosterone-producing-adenomas. Thereby, 43 pheochromocytoma patients (17 males/26 females) and 86 aldosterone-producing-adenoma patients were analyzed for body-mass-index, blood pressure, and catecholamine levels before and one year after adrenalectomy. Seventy-four percent of pheochromocytoma patients were hypertensive preoperatively and 48% one year postoperatively. Systolic blood pressure did not differ significantly in pre- and postoperative measurements whereas diastolic blood pressure was significantly reduced over time. Moreover, pheochromocytoma patients gained body weight (p<0.001) one year following adrenalectomy accompanied by significant increases in body-mass-index, whereas aldosterone-producing adenoma patients displayed a slight weight loss. Despite weight gain, diagnosis of diabetes mellitus dropped from 9 of 43 investigated pheochromocytoma patients at baseline to 4 at follow-up. A significant correlation between body-mass-index changes to the preoperative catecholamine levels was found only for urinary normetanephrines. These data suggest that normalization of chronic catecholamine excess by adrenalectomy is associated with an increase in body-mass-index, which is more pronounced in patients with high preoperative levels of urinary normetanephrines.

Key words

body mass index - adrenalectomy - catecholamines - pheochromocytoma
 

  • References

  • 1 Plouin PF, Gimenez-Roqueplo AP. Pheochromocytomas and secreting paragangliomas. Orphanet J Rare Dis 2006; 1: 49
    CrossrefPubMedGoogle Scholar
  • 2 Riester A, Weismann D, Quinkler M, Lichtenauer UD, Sommerey S, Halbritter R, Penning R, Spitzweg C, Schopohl J, Beuschlein F, Reincke M. Life-threatening events in patients with pheochromocytoma. Eur J Endocrinol 2015; 173: 757-764
    CrossrefPubMedGoogle Scholar
  • 3 Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, Ventz M, Beuschlein F, Reincke M, Reisch N, Quinkler M. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol 2009; 161: 355-361
    CrossrefPubMedGoogle Scholar
  • 4 Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366: 665-675
    CrossrefPubMedGoogle Scholar
  • 5 Zelinka T, Eisenhofer G, Pacak K. Pheochromocytoma as a catecholamine producing tumor: implications for clinical practice. Stress 2007; 10: 195-203
    CrossrefPubMedGoogle Scholar
  • 6 Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens 2011; 29: 2049-2060
    CrossrefPubMedGoogle Scholar
  • 7 Stolk RF, Bakx C, Mulder J, Timmers HJ, Lenders JW. Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines?. J Clin Endocrinol Metab 2013; 98: 1100-1106
    CrossrefPubMedGoogle Scholar
  • 8 Hamaji M. Pancreatic alpha- and beta-cell function in pheochromocytoma. J Clin Endocrinol Metab 1979; 49: 322-325
    CrossrefPubMedGoogle Scholar
  • 9 La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 2003; 21: 1703-1707
    CrossrefPubMedGoogle Scholar
  • 10 Petrak O, Haluzikova D, Kavalkova P, Strauch B, Rosa J, Holaj R, Brabcova Vrankova A, Michalsky D, Haluzik M, Zelinka T, Widimsky Jr. J. Changes in energy metabolism in pheochromocytoma. J Clin Endocrinol Metab 2013; 98: 1651-1658
    CrossrefPubMedGoogle Scholar
  • 11 Bottner A, Eisenhofer G, Torpy DJ, Ehrhart-Bornstein M, Keiser HR, Chrousos GP, Bornstein SR. Lack of leptin suppression in response to hypersecretion of catecholamines in pheochromocytoma patients. Metabolism 1999; 48: 543-545
    CrossrefPubMedGoogle Scholar
  • 12 Lean ME, James WP, Jennings G, Trayhurn P. Brown adipose tissue in patients with phaeochromocytoma. Int J Obes 1986; 10: 219-227
    PubMedGoogle Scholar
  • 13 Frontini A, Vitali A, Perugini J, Murano I, Romiti C, Ricquier D, Guerrieri M, Cinti S. White-to-brown transdifferentiation of omental adipocytes in patients affected by pheochromocytoma. Biochim Biophys Acta 2013; 1831: 950-959
    CrossrefPubMedGoogle Scholar
  • 14 Puar T, van Berkel A, Gotthardt M, Havekes B, Hermus AR, Lenders JW, van Marken Lichtenbelt WD, Xu Y, Brans B, Timmers HJ. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab 2016; 101: 224-232
    CrossrefPubMedGoogle Scholar
  • 15 Wang Q, Zhang M, Ning G, Gu W, Su T, Xu M, Li B, Wang W. Brown adipose tissue in humans is activated by elevated plasma catecholamines levels and is inversely related to central obesity. PLoS One 2011; 6: e21006
    CrossrefPubMedGoogle Scholar
  • 16 Okamura T, Nakajima Y, Satoh T, Hashimoto K, Sapkota S, Yamada E, Okada S, Fukuda J, Higuchi T, Tsushima Y, Yamada M. Changes in visceral and subcutaneous fat mass in patients with pheochromocytoma. Metabolism 2015; 64: 706-712
    CrossrefPubMedGoogle Scholar
  • 17 McCullagh EP, Engel WJ. Pheochromocytoma with Hypermetabolism: Report of Two Cases. Ann Surg 1942; 116: 61-75
    CrossrefPubMedGoogle Scholar
  • 18 Hill FD, Smith DR. Pheochromocytoma–a report of 12 cases. Calif Med 1960; 92: 125-132
    PubMedGoogle Scholar
  • 19 Raab W, Smithwick RH. Pheochromocytoma with hypothalamic manifestations and excessive hypermetabolism; a case report. J Clin Endocrinol Metab 1949; 9: 782-790
    CrossrefPubMedGoogle Scholar
  • 20 Howell LP, Roth GM, Scholz DA. Extrathyroidal hypermetabolism due to a pheochromocytoma. Minn Med 1956; 39: 792-794
    PubMedGoogle Scholar
  • 21 Agana-Defensor R, Proch M. Pheochromocytoma: a clinical review. AACN Clin Issues Crit Care Nurs 1992; 3: 309-318
    PubMedGoogle Scholar
  • 22 Stell A, Sinnott R. The ENSAT registry: a digital repository supporting adrenal cancer research. Stud Health Technol Inform 2012; 178: 207-212
    PubMedGoogle Scholar
  • 23 Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, Quinkler M, Hanslik G, Lang K, Hahner S, Allolio B, Meisinger C, Holle R, Beuschlein F, Bidlingmaier M, Endres S. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension 2012; 60: 618-624
    CrossrefPubMedGoogle Scholar
  • 24 Schirpenbach C, Segmiller F, Diederich S, Hahner S, Lorenz R, Rump LC, Seufert J, Quinkler M, Bidlingmaier M, Beuschlein F, Endres S, Reincke M. The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Dtsch Arztebl Int 2009; 106: 305-311
    PubMedGoogle Scholar
  • 25 Bosanska L, Petrak O, Zelinka T, Mraz M, Widimsky Jr. J, Haluzik M. The effect of pheochromocytoma treatment on subclinical inflammation and endocrine function of adipose tissue. Physiol Res 2009; 58: 319-325
    PubMedGoogle Scholar
  • 26 Elenkova A, Matrozova J, Zacharieva S, Kirilov G, Kalinov K. Adiponectin - A possible factor in the pathogenesis of carbohydrate metabolism disturbances in patients with pheochromocytoma. Cytokine 2010; 50: 306-310
    CrossrefPubMedGoogle Scholar
  • 27 Kang T, Gridley A, Richardson WS. Long-term outcomes of laparoscopic adrenalectomy for adrenal masses. J Laparoendosc Adv Surg Tech A 2015; 25: 182-186
    CrossrefPubMedGoogle Scholar
  • 28 Ratheiser KM, Brillon DJ, Campbell RG, Matthews DE. Epinephrine produces a prolonged elevation in metabolic rate in humans. Am J Clin Nutr 1998; 68: 1046-1052
    CrossrefPubMedGoogle Scholar
  • 29 Rathmann W, Scheidt-Nave C, Roden M, Herder C. Type 2 diabetes: prevalence and relevance of genetic and acquired factors for its prediction. Dtsch Arztebl Int 2013; 110: 331-337
    PubMedGoogle Scholar
  • 30 Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B, Lang K, Quack I, Rump LC, Willenberg HS, Beuschlein F, Quinkler M, Hannemann A. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn’s Registry. Eur J Endocrinol 2015; 173: 665-675
    CrossrefPubMedGoogle Scholar
  • 31 Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-459
    CrossrefPubMedGoogle Scholar
  • 32 Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006; 91: 3457-3463
    CrossrefPubMedGoogle Scholar
  • 33 Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, Fardella CE. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 2007; 25: 2125-2130
    CrossrefPubMedGoogle Scholar
  • 34 Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150: 776-783
    CrossrefPubMedGoogle Scholar
  • 35 Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009; 53: 605-610
    CrossrefPubMedGoogle Scholar
  • 36 Strauch B, Widimsky J, Sindelka G, Skrha J. Does the treatment of primary hyperaldosteronism influence glucose tolerance?. Physiol Res 2003; 52: 503-506
    CrossrefPubMedGoogle Scholar